Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for NEULANDLAB.BO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for NEULANDLAB.BO and 80,000+ other tickers.
See exactly how NEULANDLAB.BO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NEULANDLAB.BO and 80,000+ other tickers.
Neuland Laboratories Limited functions as a global developer and provider of active pharmaceutical ingredients (APIs), with a significant market presence in India, Europe, the United States, and other international territories. These vital compounds are employed across a diverse range of medical conditions, addressing areas such as respiratory ailments, cardiovascular health, fungal infections, convulsive disorders, central nervous system conditions, bacterial infections (including fluoroquinolone-based treatments), psychotic disorders, and Parkinson's disease. In addition to API production…
No recent news available.